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Intranasal infection of mice with certain strains of capsular group 19 Streptococcus pneumoniae can result in
focal pneumonia in the absence of bacteremia. Using this model of murine pneumonia, we demonstrated that
immunization with recombinant forms of either pneumococcal surface protein A (PspA) or PdB (a genetically
detoxified derivative of pneumolysin) elicited significant protection against focal pulmonary infection. This may
be the first demonstration that a proposed vaccine antigen can protect against pneumococcal pneumonia. The
best protection was obtained by immunizing mice with a mixture of PspA and PdB, indicating that the protection
elicited by these antigens can complement each other. This result is in agreement with previous studies that used
pneumococcal sepsis and nasal colonization models and demonstrate that the best protein vaccines for prevention
of infection may be those that include more than one protection-eliciting pneumococcal protein.
Despite their successes, pneumococcal polysaccharide
and polysaccharide-protein conjugate vaccines have not
been ideal [1–3]. These vaccines must include multiple
polysaccharide serotypes and are not protective against
strains with capsular types/groups not present in the
vaccines. Although evidence that these conjugates can
protect against pneumococcal pneumonia per se is lack-
ing, a recent report indicates that the licensed 7-valent
conjugate vaccine does result in a 20% reduction in all-
cause radiograph-positive pneumonia [4]. The com-
plexity of polysaccharide-protein conjugate vaccines
makes them expensive to produce and, at present, pre-
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cludes their use in the poorest countries where most
of the annual 3–5 million fatal respiratory infections in
young children occur [5, 6]
A possible alternative, or complementary, approach
is the use of protection-eliciting pneumococcal pro-
teins. These antigens can be produced economically as
recombinant proteins and, because they are proteins,
should avoid problems of poor polysaccharide im-
munogenicity in infants and elderly persons. The pos-
sibility of including 11 protein in a vaccine offers the
potential of targeting multiple virulence mechanisms
[7, 8].
Pneumococcal surface protein A (PspA), pneumo-
coccal surface adhesin A (PsaA), and pneumolysin are
all pneumococcal protein vaccine candidates [9–11].
PsaA and PspA elicit protection against nasal carriage
in mice [9, 12], and immunization with a mixture of
PsaA and PspA elicits better protection against carriage
than either protein alone [9]. PspA and pneumolysin
each elicit protection against bacteremia and sepsis [13,
14]. In the face of very high challenge doses of a cap-
sular type 2 strain, mixtures of PspA and pneumolysin
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were clearly more protective than either protein alone [10]. In
the present study, we have investigated the use of mixtures of
PspA, pneumolysin, and PsaA to elicit protection against mu-
rine pneumonia.
To study protection against lung infection, we needed a
model of focal pneumonia in the absence of generalized sepsis.
Most strains of pneumococci (e.g. capsular types 2–6) known
to cause disease in mice produce fatal sepsis in specific path-
ogen–free mice, whether given intravenously, intraperitoneally,
or in the lung. Pneumococci of capsular types 14, 19, and 23
are common causes of invasive disease in young children, but
they are relatively avirulent in mice [15] and are seldom used
in mouse-infection studies. Takashima et al. [16] reported that
a capsular group 19 strain could cause focal pulmonary infec-
tions in mice if given intranasally to anesthetized mice in a
large volume of inoculum. We have now provided a detailed
characterization of this model and have used the model to
evaluate the relative ability of PspA, PsaA, and pneumolysin to
elicit protection against focal pneumococcal pneumonia.
MATERIALS AND METHODS
Bacteria. S. pneumoniae capsular group 19 strains L82013
and EF3030, human isolates from the Arctic Investigations Lab-
oratory of the Centers for Disease Control and Prevention and
Gothenburg, Sweden, were obtained from Alan Parkinson and
Catharina Svanborg, respectively. Both strains are relatively
avirulent in mice by intravenous and intraperitoneal routes
[15]. Capsular group 19 strain DS2217 and type 3 strain WU2
[17, 18] were obtrained from our University of Alabama at
Birmingham laboratory collection. Capsular type 2 strains, D39
and its pneumolysin-lacking mutant PLN-A [19, 20], have been
studied in intravenous and intraperitoneal challenge studies
[10, 20, 21]. All 6 strains expressed family 1 PspA, which is
present in about half of strains recovered from carriage and
invasive disease [22, 23].
Mice. Six to 8-week-old CBA/CAHN-XID/J female mice
(denoted “CBA/N mice”; Jackson Laboratory) were maintained
under specific pathogen–free conditions. CBA/N mice have the
Btk (XID) immune-response defect [24] and fail to make nat-
ural antibodies to pneumococcal polysaccharides, including tei-
choic and lipoteichoic acids [25]. The absence of natural an-
tibodies to teichoic acids makes these mice highly susceptible
to pneumococcal infections [17] and much more reproducible
in their susceptibility than most other strains [17, 25]. All an-
imal experiments were done in accordance with the Institu-
tional Animal Care and Use Committee’s guidelines at the Uni-
versity of Alabama at Birmingham and the US Department of
Health and Human Services.
Challenge with pneumococci in pneumonia, carriage, and
bacteremia models. Pneumococci were grown [26] and frozen
in aliquots for immediate use [11]. For carriage, mice were given
the bacteria in a 10-mL volume in a single nostril. For lung
infection, the bacteria were given in a 40-mL volume in a sin-
gle nostril to mice anesthetized with methoxyflurane (Metofane;
Shering-Plough), to facilitate aspiration [27]. Intravenous in-
oculations were given in the lateral tail vein in 0.2 mL of Ringer’s
injection solution (Ringer’s; Abbot Laboratories), and mice were
observed for 21 days for deaths.
Immunization and pneumonia challenge. PspA for im-
munization was recombinant PspA/Rx1 (UAB055) [9], which
comprised the first 302 of the 558 aa of PspA/Rx1, including
all of the a-helical region and some of the proline-rich region
[28, 29]. Rx1/PspA is of PspA family 1, which is the same
family as the challenge strain EF3030 [23]. PsaA was used as
a recombinant lipidated product [30]. Pneumolysin for im-
munization was a genetically detoxified variant of pneumolysin,
PdB [31]. The molecular forms used of all 3 of these antigens
have been described elsewhere [9]. The antigens were injected
with aluminum hydroxide/magnesium hydroxide adjuvant
(Imject Alum #77161; Pierce) with 50 mg of alum per 0.2-mL
dose. Recombinant PsaA, PspA, and PdB were added to yield
concentrations of 0.5, 1.0, or 20 mg/0.2-mL dose, respectively,
and were mixed on a vertical wheel with a diameter of 15 cm
at 6 rpm for 12 h at 4C. Mice were immunized subcutaneously
in the flank in 0.2 mL of adjuvant-protein mixture. When 2
proteins were used to immunize the same mouse, the proteins
were first mixed together and then mixed with aluminum hy-
droxide. Control animals received Ringer’s and adjuvant alone.
Mice received 3 injections 14 days apart and were challenged
14 days after the last injection.
Mice were bled 7 days after challenge and were killed with
an overdose of CO2. The lungs were homogenized in 1 mL of
Ringer’s. The average weight of both lungs was ∼100 mg. The
interior of the nose was washed with 50 mL of sterile PBS [12,
32]. The numbers of colony-forming units in blood, lung ho-
mogenate, and nasal washes were enumerated, as described
elsewhere [12, 32]. In some cases, the interior of the lungs was
washed with 0.5 mL of Ringer’s before homogenization; the
number of colony-forming units in the 2 samples were quan-
titated separately.
Histology. Lungs, liver, spleen, kidney, heart, trachea, and
thyroid gland were harvested from mice that were killed at 6,
8, 28, and 38 days after infection, fixed in 10% formalin, and
embedded in paraffin. Sections were stained with Goodpasture’s
Gram stain or hematoxlyin-eosin, mounted, and examined mi-
croscopically with a 20 objective.
Phase of pneumococci. Pneumococcal phase was deter-
mined by visual inspection while pneumococci were growing on
clear agar, according to the method of Weiser [33] and Weiser
et al. [34]. Phase was assigned on a relative basis by comparing
the transparency/opacity of individual EF3030 colonies.
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Table 1. Effects of infecting anesthetized CBA/N female mice (Jackson Laboratory) mice with Streptococcus pneumoniae




















L82013 19 6.5 5 100 1120 100 0 100 100
7.6 3 67 1120 100 0 100 100
DS2117-94 19 6.5 3 100 1120 100 0 33 33
6.7 5 60 1120 100 0 100 67
EF3030 19 6.8 8 100 1120 100 0 75 75
PLN-A 2 5.0 6 100 1120 100 100 100 ND
PLN-A2b 2 6.9 5 80 1120 100 100 100 100
7.3 3 100 1120 100 100 33 100
D39 2 6.0 6 17 25 ND ND ND ND
4.0 5 20 72 100 100 100 ND
WU2 3 6.0 6 0 25 …c …c …c …c
4.0 5 20 72 100 100 100 ND
a Calculated as percentage of living mice.
b PLN-A2 is a subline of PLN-A with no known differences from PLN-A.
c No mice were still alive on day 5.
















L82013 19 6.5 5 6.56  0.29 !1.78 4.35  0.47 3.01  0.56 .029
7.6 5 5.28  0.06 !1.78 !7.59 6.71  0.27
DS2117-94 19 6.5 5 5.51  0.49 !1.78 3.80c 2.82c NS
6.7 5 6.61  0.24 !1.78 3.04  0.65 2.45  0.33
EF3030 19 6.8 5 5.30  0.27 !1.78 4.07  0.72 3.10  0.63 .010
PLN-A 2 5.0 3 4.71  0.20 5.89  0.34 …d 5.89  0.12d NA
PLN-A2e 2 6.9 5 4.65  0.22 6.08  0.58 3.50  0.30 6.04  0.46 .007
7.3 5 4.09  0.20 6.46  0.70 2.40  0.70 5.20  0.42 .021
D39f 2 4.0 3 3.15g 17.00g …d 5.58d,g NA
WU2f 3 4.0 3 3.46g 4.60g …d 5.51d,g NA
a Data are mean  SE log10 cfu/mL or cfu/pair of lungs and were calculated for mice that were still alive on day 5. P values comparing
lung wash and washed lung omit data from mice that had no detectable pneumococci in the lung and data from any dead mice. The
comparison of all group 19 lung wash vs. washed lung was significant at .Pp .0002
b Paired t test (lung wash vs. washed lung).
c Data provided are for the only mouse in this group with pneumococci in the lung.
d These lungs were not washed before homogenization.
e PLN-A2 is a subline of PLN-A with no known differences from PLN-A.
f Because all mice of this strain that were infected with 106 cfu either had died by day 5 (table 1) or were quite morbid when killed,
no data for this cfu dose were collected.
g Only 1 of 4 mice infected with WU2 and 1 of 4 mice infected with D39 survived. Thus, the colony-forming unit data for mice infected
with D39 and WU2 were obtained from only 1 mouse each.
Statistical analysis. In groups in which some mice died
before assay, the dead mice were assigned a number of colony-
forming units in the lungs slightly larger than the largest num-
ber of colony-forming units observed in the lungs for that
experiment. For carriage and bacteremia determinations, data
from dead mice were omitted, because neither carriage nor
bacteremia appeared to correlate with severity of lung infec-
tion with strain EF3030. Geometric mean numbers of colony-
forming units/tissue were determined for groups of animals
given identical treatments. The Wilcoxon 2-sample rank test
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Table 3. Effect of dose of group 19 EF3030 Streptococcus pneumoniae on lung infection 5 days after intranasal











mean  SE, log10 cfu
Nasal wash,
mean  SE, log10 cfu
4.72 3 100 0 2.41  0.43 5.52  0.11
5.80 3 100 0 4.24  0.78 5.90  0.13
6.38 4 75 0 5.46  0.33 5.67  0.01
6.87 6 100 0 6.42  0.26a 5.47  0.17
7.75 3 0 All dead All dead All dead
a One mouse in this group had no pulmonary infection and was assigned log10 of 1.70 before averaging. The minimum colony-
forming units detectable in the lung was log10 1.78
(2-tailed) was used for comparisons of experimental and con-
trol groups.
RESULTS
Ability of group 19 strains to cause lung infections. Three
capsular group 19 strains were inoculated separately intranasally
in 40 mL of inoculum into anesthetized CBA/N mice. At 5 days
after inoculation, most mice were still alive, and all surviving
mice exhibited detectable nasal carriage. More than 90% of the
mice had pneumococci in their lungs (table 1). Geometric mean
numbers of colony-forming units in the lungs ranged from
103.04 to 104.35 cfu for mice inoculated intranasally with !107.0
cfu (table 2). The geometric mean number colony-forming
units washed from the nasal tissues of the same mice ranged
from 105.2 to 106.6 cfu. None of the 3 strains successfully invaded
the blood.
To determine whether the pneumococci recovered from the
lungs were free or were tissue associated, a wash of each pair
of lungs was plated separately from a homogenate of the washed
lungs (tables 1 and 2). For mice infected with capsular group
19 pneumococci, there were 3–10 times as many pneumococci
in the wash fluid, compared to the washed lung. In contrast,
for infections with capsular type 2 strain PLN-A, there were
100 times as many pneumococci associated with the washed
lung as with the wash fluid. These results indicate that capsular
type 2 pneumococci were more invasive in the local tissue than
the group 19 pneumococci.
Virulence of EF3030 intravenous. Intravenous infection
of CBA/N mice with 100–300 cfu of D39 or WU2 is known
to result in bacteremia and death [13, 35, 36]. In contrast, when
CBA/N mice were injected intravenously with 104 or 105 cfu
of EF3030, no bacteremia was observed at 1, 4, or 7 days after
inoculation, and no mice died. At an intravenous dose of 106
cfu of EF3030, half the infected mice died within 7 days, and
virtually all exhibited bacteremia on days 1 and 4. When chal-
lenged intravenously with 107 cfu of EF3030, all mice died
within 7 days (data not shown). In other studies, we learned
that intravenous injection of 106 cfu of EF3030 produced a
chronic kidney infection, which may account for the bacteremia
seen at these doses of EF3030 (M. T. Coats [Department of
Microbiology, University of Alabama at Birmingham] and
D.E.B., unpublished data).
Intranasal challenge with type 2 and 3 strains causes bac-
teremia. Strains WU2, D39, and PLN-A were examined as
representatives of pneumococci that readily cause bacteremia and
sepsis in mice [20, 21, 35]. When anesthetized CBA/N mice were
infected intranasally with 106 cfu of D39 or WU2, all died
within only a few days (data not shown). When infected with
104 cfu of D39 or WU2, 4 of the 5 mice infected with each strain
died; median time of death was 3 days (table 1). In the 2 mice
that were still alive at 5 days, there were significant numbers of
pneumococci in the nasal wash, lungs, and blood. Only 1 of 14
mice infected with PLN-A died by day 5 (table 1). This atten-
uating effect of the pneumolysin-negative mutation is well known
[20, 21]. The geometric mean number of colony-forming units
in the nasal wash of mice given the capsular group 19 strains
was 10–100-fold higher than that for mice given type 2 or 3
strains (table 2).
Because capsular type 2 and 3 challenge strains infected the
blood so efficiently, we assumed that the early deaths caused
by intranasal infection with these strains were probably from
sepsis. To test this assumption, anesthetized mice were infected
intranasally with the type 2 strains D39 and PLN-A. At 1 and
2 days after inoculation, the colony-forming units in the blood
equaled or exceeded the colony-forming units in the lungs (data
not shown).
Because the lungs of the infected mice weighed only 0.1 g,
there would not be expected to be enough blood circulating
through the lungs to have had a significant effect on the num-
bers of colony-forming units observed in the lungs of any of
the mice in these studies.
Effects of infection dose on lung infection. When anesthe-
tized mice were intranasally given 107.75 cfu of EF3030, they all
died within 5 days. Among the 16 mice given 104.72–106.87 cfu of
EF3030, pneumococci were observed in the lungs and nasal wash,
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Figure 1. Duration of lung infection and nasal carriage after intranasal
inoculation of anesthetized CBA/N female mice (Jackson Laboratory).
Mice were inoculated with 106.88 cfu of EF3030 in a 40-mL volume of
Ringer’s solution (Abbot Laboratories) and were killed on day 7, 11, 14,
21, or 35. For both the nasal wash and the lung colony-forming–unit data,
statistical comparisons were made for each day that mice were killed,
with the pooled data from days 7 and 11. Only day-21 and day-35 nasal
wash data differed from day-7 and day-11 pooled data by these criteria.
However, comparisons between days 7–11 and days 14–35 were statis-
tically significant for both nasal wash and lung data ( andPp .023
, respectively).Pp .041
Table 4. Phase of EF3030 pneumococci recovered from the lung









7 3 63  21 0 …
11 3 60  12 0 …
14 6 70  6 0 .39
21 6 90  5 0 .065
35 3 90  8 0 .18
Pooled data
Days 7 and 11 6 62  11 0
Days 21 and 35 9 90  4 0 .036
NOTE. These are the same mice depicted in figure 1 (mice infected with
106.88 cfu of EF3030 under anesthesia). When the initial inoculum was plated, it
produced 57% opaque and 43% transparent colonies. The observed percentage
of opaque colonies for each tissue from mouse was based on at least 50 counted
colonies.
a All colonies that were not scored opaque were scored transparent.
b P values are for day 7 vs. day 11. Statistical differences were calculated by
a 2-tailed Wilcoxon 2 sample-rank test.
but not in the blood, at 5 days after challenge. Within this dose
range, the numbers of colony-forming units in the lung at 5 days
was proportional to the numbers of colony-forming units in the
original inoculum (table 3). In contrast, the numbers of EF3030
colony-forming units in the nasal washes were independent of
inoculation dose, as was observed previously [32], using a 6B
strain and inoculation without anesthesia.
Kinetics of lung infection. Anesthetized mice were inoc-
ulated intranasally with 106.88 cfu and were killed at day 7, 11,
14, 21, or 35 (figure 1). The numbers of colony-forming units
in the lung and nasal wash did not change rapidly over the 35-
day period. At each time point, all mice carried pneumococci
in their nasopharynx, and all but 1 (on day 35) had detectable
pneumococci in the lungs. The highest numbers of pneumo-
cocci in the nose were at 7 days after inoculation; the highest
numbers of pneumococci in the lung were at days 7 and 11.
Phase of pneumococci in the lung and nasal cavity. Using
other strains of pneumococci, we showed that most of the
colonies recovered from the blood were relatively opaque, com-
pared with those obtained from the nasal washes [33, 34]. For
EF3030, the differences in appearance of opaque and trans-
parent colonies was quite subtle, yet still detectable. At 7–35
days after intranasal inoculation of anesthetized mice with
EF3030, colonies of virtually all the pneumococci washed from
the nasal cavity were transparent. At these time points, the
majority (60%–90%) of colonies of pneumococci recovered
from the lungs were opaque (table 4). The EF3030 inoculum
was 57% opaque and 43% transparent.
Although there was much variation in the percentage of
opaque colonies of pneumococci recovered from the lungs at
the first few time points, there was a significant increase in the
percentage of opaque colonies recovered from the lung with
time (table 4). The percentages of opaque colonies from lungs
harvested on days 21 and 35 was significantly higher (Pp
) than those recovered from the lungs harvested at days 7.036
and 11. Although the percentage of opaque colonies from the
lung was not much higher than that of the inoculum (57%),
it probably reflects a true steady-state value for the lungs. In
separate studies, mice were inoculated with cultures of EF3030
exhibiting 18% and 95% opaque colonies. For mice that re-
ceived each inoculum, the day 21 lungs yielded ∼90% opaque
colonies (data not shown).
Importance of aspiration in lung infections. In previous
studies [16] and in the results described above, anesthetized mice
were inoculated intranasally with a rather large volume of in-
oculum (40 mL). The importance of this procedure for facilitating
aspiration is apparent from a comparison of the aspiration pro-
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Table 5. Effect of inoculation protocol on lung infection with capsular group 19
strain EF3030.
Parameter Nasala Aspirationa Pb
Log cfu inoculated 5.73 5.73
Anesthesia No Yes
Inoculum volume 10 mL 40 mL
Log cfu/mL blood !2.78 (NA) !2.78 (NA) NS
Log cfu/lungs 2.81  0.42 (1.78–3.43) 6.05  0.42 (4.67–7.17) .0079
Log cfu/nose wash 5.11  0.17 (4.67–5.51) 6.10  0.17 (5.70–6.54) .0159
Percentage opaque
Lungs 95  4 (77–100) 95.6  2.9 (85–100) NS
Nasal wash 20.6  14.4 (2–78) 22.8  5.4 (13–38) NS
NOTE. Data are mean SE log (range), unless otherwise indicated. Each group contained 5
mice. NA, not applicable; NS, not significant.
a “Nasal” protocol was inoculation in 10mL without anethesia. “Aspiration” protocolwas inoculation
in 10 mL with anesthesia.
b Nasal vs. lung.
tocol with a standard protocol [32] for inducing nasal carriage
in adult mice (intranasal inoculation with 10 mL without anes-
thesia) (table 5). Although there were 10 times as many pneu-
mococci washed from the nose of mice infected with the aspi-
ration method, both procedures yielded solid carriage in all mice.
However, when colony-forming units in the lungs were com-
pared, there were ∼2000 times as many colony-forming units in
the mice inoculated with the aspiration method as with the car-
riage protocol. Thus, the progression of large numbers of pneu-
mococci into the lung appears to require aspiration and is not
a natural consequence of nasal colonization. This conclusion is
supported by a previous study that used capsular type 6B pneu-
mococci and the carriage protocol, in which even fewer pneu-
mococci were observed in the lungs [32].
The larger numbers of pneumococci in the nasal passages
in the aspiration-pneumonia model, compared with those in
the carriage model might be explained by the movement of
pneumococci from the infected lung to the nose or by the ability
of the larger inoculation volume to cover more of the nasal
tissue and to colonize larger fractions of niche space.
Histology of infected mice. Histological examination of
the lungs removed at 6 and 8 days post inoculation revealed
acute pneumonia in one or more lobes of the lungs of each
mouse inoculated with EF3030 under anesthesia (figure 2B).
Alveoli of the infected animals contained neutrophils, mono-
cytes and necrotic debris. Noninfected mice had normal lungs
with clear alveoli (figure 2A). A small number of diplococci,
typical of S. pneumoniae, could be observed in gram-stained
lungs of one of the 5 infected mice examined at these time
points (data not shown). There was no evidence of infection
in the livers or kidneys. Spleens of infected mice showed in-
creased numbers of neutrophils in the sinuses, and extramedul-
lary hematopoiesis also was detected.
Consistent with the decrease in numbers of colony-forming
units in the lungs at the later time points (figure 1B), day 28
and day 38 histologic examinations showed evidence of heal-
ing. Only 1 of the 3 mice examined at the day 28 time point
and none at the day 38 time point showed evidence of acute
pneumonia. Most of these lungs showed bronchioles filled with
fibrin and macrophages consistent with focal proliferative bron-
chiolitis. These same lungs showed occasional perivascular lym-
phocytic infiltrates with focal invasion of the vessel walls. Al-
veoli showed foamy macrophages and some had collagen
deposition. In general, less pathology was seen at day 38 than
at day 28 after infection. Kidneys, livers, and spleens were
unremarkable.
Although the bacteria were frequently more numerous in the
nasal cavities than in the lungs (table 2), the bulk of the mucosal
surface showed no pathology. However, the focal lesions that
were seen included scattered lymphocytes within the mucosa,
loss of cilia, and, on rare occasions, clusters of neutrophils in
nasal crypts (data not shown).
Immunogenicity of PspA, PdB, and PsaA administered sub-
cutaneously with alum in CBA/N mice. CBA/N mice were
immunized with PspA, PsaA, PdB, and pair-wise combinations
of the 3 antigens. PspA, PsaA, and PdB were given at doses of
1, 0.5, and 20 mg, respectively, and mice received 3 injections
of the indicated antigens with alum at 2-week intervals. The
differences in the doses of the 3 antigens was an attempt to
compensate for anticipated differences in their immunogenicity
[9]. Thirteen days after the last injection, the mice were bled
for IgG antibody determinations and, on day 14, were anes-
thetized and challenged intranasally. Of the 3 immunogens, the
highest IgG antibody responses were elicited by the lipidated
PsaA, despite the fact that this antigen was given at a dose half
that of PspA. The lowest antibody levels were elicited by PdB,
even though it was given at a dose 20 times that of PspA (table
6). Although there appeared to be some differences in the an-
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Figure 2. Sections of normal (A) and infected (B) lung stained with hemotoxylin-eosin. Anesthetized CBA/N female mice (Jackson Laboratory) were
infected with 106.8 cfu of EF3030 in 40-mL Ringer’s injection solution (Abbot Laboratories) or with sterile Ringer’s injection solution. Lungs were
harvested and sectioned 6 days later and stained with hematoxylin-eosin. Original magnification, 400.
tibody responses to antigens alone and in mixtures, none of
these differences were statistically significant ( , WilcoxonP 1 .12
2-sample rank test).
Protection against lung infection by immunization with
pneumococcal proteins. We used the highest challenge dose
of EF3030 (∼106.8 cfu) that did not cause death before day 5.
The protection experiments were assayed at day 7 to maximize
the numbers of pneumococci in the lungs. Immunizations with
PspA and PdB resulted in significant protection against pul-
monary infection (figure 3). Immunization with PsaA yielded
no decrease in numbers of pneumococci in the lungs of the
infected mice, although it elicited 6–60 times higher antibody
levels than did PspA or PdB. When the proteins were injected
in pair-wise combinations, immunity to PsaA also failed to
significantly enhance the protection elicited by PspA or PdB.
The most dramatic protection against lung infection was
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Table 6. IgG antibody elicited by subcutaneous immunization
with pneumococcal surface protein A (PspA), pneumococcal sur-
face adhesin A (PsaA), and pneumolysin.
Immunogen
Serum IgG antibody levels,
geometric mean (SE factor), mg/mL
PspA PdB PsaA
Alum !0.001 !0.0005 !0.004
PspA 7.89 (1.72) !0.0005 !0.004
PsaA !0.001 !0.0005 219 (1.38)
PdB !0.001 17.38 (1.48) !0.004
PspA + PdB 17.0 (1.34) 9.53 (2.09) !0.004
PspA + PsaA 32.4 (1.26) !0.0005 347 (1.66)
PdB + PsaA !0.001 6.25 (1.35) 407 (1.21)
NOTE. CBA/N female mice (Jackson Laboratory; 6 animals/ group) were
immunized with PspA, PsaA, PdB, and binary combinations of these proteins on
alum. Three subcutaneous immunizations were given at 2-week intervals. The
doses of the 3 proteins per immunization were 1, 0.5, and 20 mg/mouse for PspA,
PsaA, and PdB, respectively. Mice were bled 13 days after the last injection of
antigen and/or alum. The SE factor is the number by which the geometric mean
must be multiplied and divided to obtain the lower and upper bounds or SE).
Figure 3. Immunization with pneumococcal surface protein A (PspA)
and PdB (a genetically detoxified derivative of pneumolysin) can protect
against pulmonary infection with Streptococcus pneumoniae. CBA/N female
mice (Jackson Laboratory) were immunized with the indicated proteins on
alum or with alum alone, challenged with 106.89 cfu of capsular group 19
strain EF3030, and killed 7 days later to determine numbers of colony-
forming units in their lungs and nasal cavity (nasal data shown). PsaA,
pneumococcal surface adhesin A; * ; ** .P .04 P ! .001
obtained by immunization with a combination of PspA and
PdB, which reduced the number of lung colony-forming units
110-fold than that achieved with PspA and 1100-fold than that
achieved with PdB. This observation was confirmed in a second
experiment (data not shown) using groups of 10 mice im-
munized with alum only, PspA plus alum, PdB plus alum, and
a mixture of PspA and PdB plus alum. As in the previous
experiment, we observed highly significant protection, com-
pared with that of the alum control, for immunity to PspA,
PdB, or PspA plus PdB ( , , and , re-P ! .007 P ! .01 P ! .0003
spectively). In the second experiment, the numbers of colony-
forming units in the lungs of the mice immunized with the
mixture of PspA and PdB was 1/245th of that in the lungs of
mice injected with alum only. By pooling the results from these
groups of 10 mice with the results from the groups of 6 similarly
immunized mice in the first experiment (figure 3), we observed
greater protection with the mixture of PspA and PdB, compared
with that of PspA or PdB alone ( and ,Pp .048 Pp .0004
respectively). Immunization with PspA, PdB, and/or PsaA had
no effect on nasal carriage of pneumococci in mice with pneu-
monia (data not shown).
DISCUSSION
Our observation that subcutaneous immunization with a mixture
of PspA and pneumolysin was especially protective against pneu-
monia in mice also was reminiscent of the fact that PspA and
pneumolysin also provided optimal protection against intra-
peritoneal challenge [10]. These findings strengthen the conclu-
sion that the combination of these 2 antigens may be especially
useful for eliciting protection against systemic pneumococcal in-
fection. The absence of bacteremia and sepsis in the aspiration-
pneumonia infection model means that the observed protection
against lung infection was the result of direct protection in the
lung, rather than an indirect outcome of protection against sep-
ticemia. The aspiration-pneumonia infection model exhibited an
intense, but self-resolving, pneumonia. This model is especially
relevant to human disease, because it mimics the situation with
a large number of the human lung infections that are caused by
aspiration of pneumococci, in which bacteremia is not apparent
at the time of admission or treatment.
The reduced invasion of the group 19 strains versus the
capsular type 2 and 3 strains was seen not only in the failure
of the group 19 strains to invade the blood but also in their
lower propensity to invade from the lumen of infected lungs
into the pulmonary tissue. The lack of apparent invasion of
the group 19 strains does not necessarily mean that they do
not enter the blood, but may be a result of their inability, as
was demonstrated here, to survive in the circulation.
Studies by Weiser and his colleagues [33, 34] have shown
that pneumococci exhibit phase variation in colony opacity;
pneumococci recovered from the nasal surface and blood tend
to be transparent and opaque, respectively. As expected, EF3030
washed from the nose were virtually all transparent. Our ob-
servation that the colonies from the lung were largely opaque
has not been previously reported and indicates that pneumo-
cocci treat the lung as an invasive site.
The difference in expression of virulence factors by the trans-
parent and opaque pneumococci [33, 34] may partially explain
why S. pneumoniae cause much less inflammation in the nose
than in the lung. This difference in inflammation at these 2 sites
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is a graphic demonstration of the degree to which the pneumo-
coccus has evolved to asymptomatically colonize the upper air-
ways, although the host still recognizes it as an inflammatory
pathogen once it enters the lung.
The fact that PspA and pneumolysin elicited additive protec-
tion against pneumonia suggests that the antibodies to them may
interfere with complementary virulence functions. PspA has been
shown to interfere with activation of complement by pneumo-
cocci during their infection of mice [37, 38]. Antibody to PspA
is thought to enhance surface deposition of complement by in-
terfering with the anticomplementary activity of PspA. It has
been shown that the ability of pneumolysin released from pneu-
mococci to fix complement is an important mediator of disease
[39, 40]. Antibody to pneumolysin is thought to act, in part, by
interfering with pneumolysin’s ability to reduce the local con-
centration of complement, thus making more complement avail-
able for deposition on the pneumococcal surface [41]. The an-
tibodies to PspA and pneumolysin may act together to increase
the amount of complement deposited on the bacterial surface,
thus increasing opsonization, phagocytosis, and killing. The ob-
servation that elevated levels of serum antibody to these antigens
can protect against pneumonia is consistent with the fact that
serum (with its antibody and complement) is known to be ex-
travasated into alveoli during inflammation [42].
Nasopharyngeal carriage is generally considered to be the pri-
mary human reservoir of pneumococci. Protection against nasal
carriage is considered to be essential for herd immunity to pneu-
mococci. Moreover, because nasopharyngeal carriage is thought
to be an intermediate stage that precedes invasive disease [43],
protection against carriage also should have a direct effect on the
reduction of invasive disease. In previous studies, mucosal im-
munization with PsaA (and, to a lesser extent, PspA) was able
to elicit protection against nasal carriage. The best protection
against carriage was obtained with mice immunized with both
PsaA and PspA [9].
Our observation here that subcutaneous immunization with
pneumolysin, PspA, and/or PsaA did not protect against nasal
colonization of the mice in the aspiration-pneumonia infection
model is consistent with previous studies in a mouse carriage
model, in which systemic immunization with PspA was not
able to protect against nasal carriage, although mucosal im-
munization could [12]. The failure of PsaA to elicit protection
against pulmonary infection in this model does not necessarily
argue against its inclusion in a mucosal vaccine, in which it
might elicit protection against carriage and thus prevent sub-
sequent pneumonia.
From the results of these pneumonia studies, as well as those
of the earlier studies with sepsis and carriage models [9, 10], it
seems likely that mucosal immunization of humans with a mix-
ture of PspA, PdB, and PsaA might represent an especially ef-
fective strategy. PsaA and PspA could elicit protection against
carriage and confer herd immunity. Because mucosal immuni-
zations also can produce protective levels of serum antibody [12]
the PspA and pneumolysin would be able to elicit protection
against any pneumococcal pneumonia or bacteremia that oc-
curred in individuals who still carried some S. pneumoniae.
If immunity to these proteins proves to be as effective in
humans as the conjugate vaccines, the proteins could have some
important advantages. Most importantly, the protection would
be independent of capsular type. The protective responses
would be T cell dependent and thus immunogenic, like the
conjugate vaccine, in children. Unlike the protein carrier in the
conjugate vaccine, the pneumococcal proteins will also be pre-
sented to T cells by infecting pneumococci. Thus, these pneu-
mococcal proteins will be able to help elicit anamnestic re-
sponses among helper T cells as well as among B cells, thus
possibly eliciting stronger anamnestic responses to infections.
This theoretical advantage also argues for the use of these pro-
teins as carriers for pneumococcal polysaccharides.
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